Summary & Overview
CPT 81260: Technical Molecular Test for IKBKAP Gene Variants
CPT code 81260 represents the technical laboratory component for molecular testing that detects common sequence changes in the IKBKAP gene. This diagnostic lab service is clinically important for identifying genetic variants that can inform diagnosis and management of conditions linked to IKBKAP. Nationally, accurate coding for genetic tests like 81260 matters for appropriate laboratory reimbursement, consistent clinical documentation, and downstream claims processing.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing considerations for the technical component, and typical sites where the service is performed.
Readers will learn the clinical context of testing for IKBKAP gene changes, the service type and usual laboratory setting, and what to expect in terms of billing line items tied to the technical component of the assay. Data availability and specific payer policy details vary; where detailed benchmark or policy information is not available in the input, the document notes that data is not available in the input. The summary provides a concise reference for clinicians, laboratory billing staff, and policy analysts working with genetic test claims.
Billing Code Overview
CPT code 81260 describes a technical laboratory test performed to detect common changes in the IKBKAP gene (inhibitor of kappa light polypeptide gene enhancer in B–cells, kinase complex–associated protein). The service is a molecular genetic test that analyzes patient DNA to identify sequence variants in the IKBKAP gene associated with relevant clinical conditions.
Service Type: Molecular genetic testing / Genetic diagnostic laboratory service
Typical Site of Service: Clinical molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a child or adult with clinical features suggesting familial dysautonomia or suspected mutations in the IKBKAP gene (e.g., autonomic dysfunction, failure to thrive, absent deep tendon reflexes, insensitivity to pain, or family history of known carrier status). The clinical workflow begins with a clinician (often a geneticist, neurologist, or pediatrician) obtaining informed consent and a blood or saliva sample. The sample is sent to a molecular diagnostics laboratory where a molecular technologist or lab analyst performs targeted sequencing or mutation analysis directed at common IKBKAP gene changes using methods such as PCR-based assays, allele-specific oligonucleotide testing, or targeted next-generation sequencing. Results are reported to the ordering provider and incorporated into the patient’s medical record; positive or carrier findings prompt genetic counseling, cascade testing of family members, and coordination of care with specialists as appropriate. Typical sites of service include outpatient clinical laboratories, hospital-based molecular diagnostic labs, academic medical center genetics laboratories, and reference diagnostic laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting the physician or pathologist professional interpretation separate from the technical test performed by the lab. |